BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. - Wikidata - awgldk - TriplyDB

BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence.

BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence.

http://www.wikidata.org/entity/Q36413759

about

Risk Stratification in Differentiated Thyroid Cancer: An Ongoing Process Progress in molecular-based management of differentiated thyroid cancer BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases.New insights in risk stratification of differentiated thyroid cancer.Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.Diagnostic value of BRAF (V600E)-mutation analysis in fine-needle aspiration of thyroid nodules: a meta-analysis.Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma Annual financial impact of well-differentiated thyroid cancer care in the United States.Translational research in endocrine surgery.BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma.BRAF mutation in fine-needle aspiration specimens as a potential predictor for persistence/recurrence in patients with classical papillary thyroid carcinoma larger than 10 mm at a BRAF mutation prevalent area.Clinical impact of BRAF mutation on the diagnosis and prognosis of papillary thyroid carcinoma: a systematic review and meta-analysis.Disease Progression in Papillary Thyroid Cancer with Biochemical Incomplete Response to Initial Therapy.The changing landscape of papillary thyroid cancer: Epidemiology, management, and the implications for patients.Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.The BRAF V600E mutation predicts poor survival outcome in patients with papillary thyroid carcinoma: a meta analysis Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.A new strategy for the surgical management of RLN infiltrated by well-differentiated thyroid carcinoma.Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma.Associations of the BRAF (V600E) mutation and p53 protein expression with clinicopathological features of papillary thyroid carcinomas patients.The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis.Circulating BRAFV600E levels correlate with treatment in patients with thyroid carcinoma.BRAF V600E detection in cytological thyroid samples: A key component of the decision tree for surgical treatment of papillary thyroid carcinoma.Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.BRAF(V600E) mutation analysis in papillary thyroid carcinoma: is it useful for all patients?

P2860

Q26765083-02F8E56D-78ED-46C0-BFF6-A9E18A337E83 Q26999887-CE3B25F2-5EE0-41B3-8B0C-E490157A05EF Q28075975-3222D649-363D-450C-BE01-1A280E65B4FF Q30367068-1F7E83F7-FB34-43CE-82B0-CDBCD8995369 Q33713817-1C29605B-0CC7-44AD-A958-972203C1A090 Q33875906-C0A77C3C-A1B6-46BB-A434-D5054BF580B0 Q33915384-A01B54B7-9A9B-4E92-876E-3449D0A10E02 Q33918101-4C9CF2CC-74FD-43BA-86DE-02B17DBBBDF0 Q36016602-19ABAA33-7109-4A37-9D9B-867679866DD9 Q36468764-A59572ED-019B-4C22-90C4-C2249D663870 Q37722349-99B11EC7-D593-425C-983E-C3D0EA0F8983 Q38135137-4AC94EBF-25FA-4987-983F-91FEE83DF117 Q38194099-E4564E9C-F06F-440F-B422-379EC62769DA Q38438138-4CB53C07-5F76-42CF-826F-0658A1B96D75 Q38663177-E18C3576-214A-4354-A290-0017443AAD3D Q38741579-58171891-0843-442B-BCD5-B44835D42374 Q38831911-C2101C83-A302-4A4D-9805-1DD0FF6C07F1 Q38886234-ED62DA6B-ABBC-4DA5-BDA0-11B912D50BDE Q39991469-E88728E7-FB98-498F-9E74-3C4E4C6FA57C Q40093937-87AAB7D6-21E3-4640-9726-4E624A12421D Q40556671-BC3C6BA4-AE02-4FDC-A54B-707D20D74586 Q41665358-5AC52109-C256-43DD-BCF7-CA7833C9F41B Q42456317-7643EEF2-6B12-4E0A-A9E1-70E136783A47 Q43740818-0F7A9B51-04F0-4D1F-BBB8-7EF14A3B671B Q49600551-98A45E82-94B0-4259-8E21-99343F6ECD43 Q50882606-E48FFD34-E0C7-43CF-8409-5E50B0B51FD2 Q53436291-C475C7D4-1C14-47FF-9904-680216DCC1B4 Q54407999-A0F3279E-19D6-416E-A93A-F900A5D51546

P2860

BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence.

http://www.wikidata.org/entity/Q36413759

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

BRAF V600E status adds increme ...... thyroid carcinoma recurrence.

@ast

BRAF V600E status adds increme ...... thyroid carcinoma recurrence.

@en

type

label

BRAF V600E status adds increme ...... thyroid carcinoma recurrence.

@ast

BRAF V600E status adds increme ...... thyroid carcinoma recurrence.

@en

prefLabel

BRAF V600E status adds increme ...... thyroid carcinoma recurrence.

@ast

BRAF V600E status adds increme ...... thyroid carcinoma recurrence.

@en

P1433

Q36413759-A1B91B03-F319-4F68-B5D9-755CAE04C6A0

P1476

Q36413759-73CC538D-ED67-4F13-830A-8E2BB5BD26CC

P2093

Q36413759-3DB08C75-7DA8-4710-B88E-C8A68144D526

Q36413759-4098588F-E371-4467-BA3C-A04C2A2A0FDF

Q36413759-62F05718-F696-4F5D-857F-88176E00CD43

Q36413759-647BC435-E4C7-4ED4-9358-5A4FC116C773

Q36413759-65C1B71E-1093-450C-9725-EB66A96288AB

Q36413759-C2CFBFF9-40D4-4608-91B7-76A47C591354

Q36413759-C890A463-6C06-414A-B860-B65E36FC606E

Q36413759-CE027B91-7419-40DA-AF21-9985157ED1E9

Q36413759-EBEFAD46-E05E-4471-8F86-03092852520F

P2860

Q36413759-23C3D2AA-548B-4EE5-B6F3-6F7860B38DC2

Q36413759-2AC7590D-0EE8-4241-B13F-145968B54424

Q36413759-2F0C0641-4DB8-45C4-9B47-07CE2A1B07C0

Q36413759-3BE880A3-7EA6-467D-BAA8-E83F1D533D0F

Q36413759-47353A57-F2D9-4701-98C9-4BB228583D69

Q36413759-4FBA15BC-2154-49BB-979A-14F43F37CDF0

Q36413759-5D3E5FEF-FABF-4DED-B1CE-340312983819

Q36413759-84FF3E04-A793-453F-AF35-B06474359956

Q36413759-855B006F-6C04-4E86-8756-78BB5933171C

Q36413759-900E57EB-104E-41C6-BA8E-761A62F50712

P304

Q36413759-254AD4A6-C2FA-4BD0-A367-5C338C96D358

P31

Q36413759-D1F691D8-5745-4B8E-91A4-8A218611E13A

P356

Q36413759-641B814A-4CA0-4F71-9348-A50BB1652085

P407

Q36413759-730C5F47-87FF-4E9C-A548-7533A437738D

P433

Q36413759-7B056358-D3C7-497E-8D73-540AD8534A14

P478

Q36413759-F711D356-F6E8-4464-BC07-C8D11FAEB9B3

P50

Q36413759-B3AE5929-187E-41C3-B6E3-91AD678DD4DE

P577

Q36413759-9FB57E24-A957-4D08-A32D-B67188409C5C

P5875

Q36413759-623BD57F-1DCF-4B71-AFB2-E861DED73512

P698

Q36413759-CE5EE190-1D6F-4C6F-B81A-60DA8681225B

P932

Q36413759-43C7D849-F327-43C4-820A-6DD274AA9B6C

P356

J.SURG.2012.08.039

P1433

P1476

BRAF V600E status adds increme ...... y thyroid carcinoma recurrence

@en

P2093

Antonia E Stephen

http://www.w3.org/2001/XMLSchema#string

Carrie C Lubitz

http://www.w3.org/2001/XMLSchema#string

Gilbert H Daniels

http://www.w3.org/2001/XMLSchema#string

Gregory W Randolph

http://www.w3.org/2001/XMLSchema#string

Jason D Prescott

http://www.w3.org/2001/XMLSchema#string

Long Phi Le

http://www.w3.org/2001/XMLSchema#string

Randall D Gaz

http://www.w3.org/2001/XMLSchema#string

Richard A Hodin

http://www.w3.org/2001/XMLSchema#string

Sareh Parangi

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations of the BRAF gene in human cancer

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

Proliferative nodules arising within congenital melanocytic nevi: a histologic, immunohistochemical, and molecular analyses of 43 cases

Role of prophylactic central neck dissection in cN0 papillary thyroid cancer.

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005.

Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989.

Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.

P304

984-990

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.SURG.2012.08.039

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

152

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233535546

http://www.w3.org/2001/XMLSchema#string

P698

23158172

http://www.w3.org/2001/XMLSchema#string

P932

3502879

http://www.w3.org/2001/XMLSchema#string